Previous 10 | Next 10 |
2023-08-01 01:59:28 ET Summary After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz,...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced today it will report financial results for the second quarter of 2023 after market close on Thursday, Augu...
2023-06-23 13:41:41 ET Summary Pulse Biosciences' Nano-Pulse Stimulation technology is showing promise in various treatments. The company is also exploring the use of its nsPFA technology in treating atrial fibrillation, potentially expanding its addressable market. Despite th...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced nsPFA will be featured in three presentations at the upcoming Heart Rhythm 2023 Annual Meeting in Ne...
2023-05-11 21:59:07 ET Pulse Biosciences, Inc. (PLSE) Q1 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer ...
2023-05-11 16:15:52 ET Pulse Biosciences press release ( NASDAQ: PLSE ): Q1 GAAP EPS of -$0.26 misses by $0.04 . Cash and cash equivalents totaled $54.1 million as of March 31, 2023, compared to $12.7 million as of March 31, 2022 and $61.1 million as of December 31, 20...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023. Business Updates ...
2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...
2023-05-10 14:01:00 ET Pulse Biosciences ( NASDAQ: PLSE ) on Wednesday said it intends to redeem all of the common stock warrants that were issued as part of its June 9, 2022 rights offering which are still outstanding as of June 16, 2023. The company plans to deliver re...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced that it intends to deliver an irrevocable notice of redemption, on or about May 15, 2023, to...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the fi...
2024-06-25 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...